NO2324113T3 - - Google Patents
Info
- Publication number
- NO2324113T3 NO2324113T3 NO09805653A NO09805653A NO2324113T3 NO 2324113 T3 NO2324113 T3 NO 2324113T3 NO 09805653 A NO09805653 A NO 09805653A NO 09805653 A NO09805653 A NO 09805653A NO 2324113 T3 NO2324113 T3 NO 2324113T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8750408P | 2008-08-08 | 2008-08-08 | |
| US21860309P | 2009-06-19 | 2009-06-19 | |
| PCT/US2009/053249 WO2010017542A1 (en) | 2008-08-08 | 2009-08-10 | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2324113T3 true NO2324113T3 (enExample) | 2018-07-28 |
Family
ID=41664003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO09805653A NO2324113T3 (enExample) | 2008-08-08 | 2009-08-10 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8841120B2 (enExample) |
| EP (2) | EP2324113B8 (enExample) |
| JP (3) | JP5852883B2 (enExample) |
| KR (2) | KR101793161B1 (enExample) |
| CN (2) | CN102177233B (enExample) |
| AU (1) | AU2009279456B2 (enExample) |
| CA (1) | CA2733589C (enExample) |
| DK (1) | DK2324113T3 (enExample) |
| ES (1) | ES2668836T3 (enExample) |
| HK (1) | HK1215051A1 (enExample) |
| NO (1) | NO2324113T3 (enExample) |
| PL (1) | PL2324113T3 (enExample) |
| SG (1) | SG2013057732A (enExample) |
| WO (1) | WO2010017542A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007345768B2 (en) * | 2006-07-27 | 2013-08-01 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| EP2641613A1 (en) | 2006-09-29 | 2013-09-25 | Ligocyte Pharmaceuticals, Inc. | Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant |
| SG10201701988TA (en) | 2007-03-14 | 2017-04-27 | Ligocyte Pharmaceuticals Inc | Virus like particle purification |
| CN101918028B (zh) | 2007-09-18 | 2015-01-07 | 莱戈赛特医药股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| EP2324113B8 (en) | 2008-08-08 | 2018-04-04 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| AU2011276328C1 (en) * | 2010-07-06 | 2016-01-21 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| MX356586B (es) | 2011-07-11 | 2018-06-05 | Takeda Vaccines Inc | Formulaciones parenterales de vacunas contra los norovirus. |
| EP2747778B1 (en) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| JP6567824B2 (ja) * | 2011-10-12 | 2019-08-28 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| KR20150130438A (ko) | 2013-03-12 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 인간 파밀로마 바이러스용 개선된 백신 및 이것을 사용하는 방법 |
| JP2015015931A (ja) | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ウイルス様粒子を含む培養物の製造方法 |
| JP6479305B2 (ja) | 2013-07-12 | 2019-03-06 | 株式会社Ｕｍｎファーマ | ウイルス様粒子の精製方法 |
| US10524493B2 (en) * | 2013-09-16 | 2020-01-07 | The Johns Hopkins University | Compositions and methods for preventing or relieving symptoms of infections |
| CA2926225A1 (en) | 2013-10-03 | 2015-04-09 | Takeda Vaccines, Inc. | Methods of detection and removal of rhabdoviruses from cell lines |
| EP3074051A4 (en) | 2013-11-29 | 2017-04-12 | The Trustees Of The University Of Pennsylvania | Mers-cov vaccine |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| WO2017040203A1 (en) * | 2015-08-28 | 2017-03-09 | Yoshihiro Kawaoka | Generation of infectious influenza viruses from virus-like particles |
| EP3341019A4 (en) | 2015-08-28 | 2019-07-31 | Ology Bioservices, Inc. | NOROVIRUS VACCINE |
| CN106831958B (zh) * | 2015-12-04 | 2020-12-29 | 厦门大学 | 一种人乳头瘤病毒11型l1蛋白的突变体 |
| JP2019510481A (ja) | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ワクチン開発のための改善されたｂ型インフルエンザウイルス複製 |
| BR112018074853A2 (pt) | 2016-06-03 | 2019-04-02 | Quest Diagnostics Investments Llc | métodos para detectar a presença de pelo menos um genogrupo de norovírus em uma amostra de fezes e para selecionar um paciente que sofre de gastroenterite aguda, e, kit |
| WO2018170603A1 (en) * | 2017-03-23 | 2018-09-27 | Medicago Inc. | Norovirus fusion proteins and vlps comprising norovirus fusion proteins |
| EP3604540A4 (en) | 2017-03-31 | 2020-12-23 | The University of Tokyo | NOROVIRUS ANTIBODIES |
| JP6795468B2 (ja) * | 2017-07-14 | 2020-12-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| US11566050B2 (en) | 2017-10-18 | 2023-01-31 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus vaccines and diagnostics |
| EP3700562A1 (en) | 2017-10-25 | 2020-09-02 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
| CN109776657B (zh) * | 2017-11-14 | 2021-11-26 | 北京康乐卫士生物技术股份有限公司 | 重组诺如病毒vlp颗粒和制备方法及其用途 |
| EP3717648A4 (en) * | 2017-11-30 | 2021-12-01 | Medicago Inc. | MODIFIED NOROVIRUS VP1 PROTEINS AND VLPS WITH MODIFIED NOROVIRUS VP1 PROTEINS |
| US11918646B2 (en) | 2017-12-11 | 2024-03-05 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| BR112020024694A2 (pt) * | 2018-06-04 | 2021-03-09 | Xiamen University | Mutante de proteína l1 do tipo 39 de papilomavírus humano |
| KR102075393B1 (ko) * | 2018-06-28 | 2020-02-11 | 한국과학기술원 | 중증 열성 혈소판 감소 증후군(sfts) 바이러스 감염 질환 예방 또는 치료용 백신 조성물 |
| JP7429684B6 (ja) * | 2018-07-13 | 2024-03-15 | メディカゴ インコーポレイテッド | 改変ノロウイルスｖｐ１タンパク質および改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| US20210308249A1 (en) | 2018-08-20 | 2021-10-07 | Takeda Vaccines, Inc. | Vlp formulations |
| AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| JP7075130B2 (ja) * | 2019-10-25 | 2022-05-25 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| WO2021150874A1 (en) | 2020-01-24 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized na |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN114316033A (zh) * | 2020-09-29 | 2022-04-12 | 香港理工大学深圳研究院 | 一种特异性识别诺如病毒的单克隆抗体及制备方法与应用 |
| EP4273155A4 (en) * | 2020-12-30 | 2025-03-12 | Grand Theravac Life Science (Nanjing) Co., Ltd. | NOROVIRUS VIRUS-LIKE PARTICLE, IMMUNE COMPOSITION OR KIT AND USE THEREOF |
| EP4342989A4 (en) * | 2021-05-20 | 2024-09-25 | Denka Company Limited | ANTI-NOROVIRUS ANTIBODIES |
| EP4340874A1 (en) | 2021-05-21 | 2024-03-27 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
| JP2024538677A (ja) | 2021-10-04 | 2024-10-23 | タケダ ワクチン，インコーポレイテッド | ノロウイルス反応性抗体を決定する方法 |
| EP4499138A1 (en) * | 2022-03-25 | 2025-02-05 | Merck Sharp & Dohme LLC | Controlled release vaccine formulations |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| WO1992016543A1 (en) | 1991-03-25 | 1992-10-01 | Genelabs Incorporated | NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs |
| JPH07509122A (ja) * | 1992-04-08 | 1995-10-12 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ レプリゼンテッド バイ ザ セクレター，デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 野生型麻疹ウイルス糖タンパク質：ワクチンおよびその検出方法 |
| AU4851493A (en) | 1992-09-07 | 1994-03-29 | Baylor College Of Medicine | Methods and reagents to detect and characterize norwalk and related viruses |
| US5788970A (en) * | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
| AU693203B2 (en) * | 1994-05-16 | 1998-06-25 | Merck Sharp & Dohme Corp. | Papillomavirus vaccines |
| US5645051A (en) * | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
| US5861241A (en) * | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
| GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| US5953727A (en) * | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
| US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| CA2288129A1 (en) * | 1997-05-01 | 1998-11-12 | Chiron Corporation | Use of virus-like particles as adjuvants |
| US20040265377A1 (en) * | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
| SK2232001A3 (en) * | 1998-08-14 | 2001-08-06 | Merck & Co Inc | Process for purifying human papillomavirus virus-like particles |
| ATE323508T1 (de) | 1998-12-17 | 2006-05-15 | Merck & Co Inc | Synthetische virus-ähnliche partikel mit heterologen epitopen. |
| ES2398413T3 (es) * | 1999-06-22 | 2013-03-19 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Kit de detección de SRSV |
| JP2002020399A (ja) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体 |
| AU2003217413A1 (en) * | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Method for isolation and purification of expressed gene products in vitro |
| PL375306A1 (en) * | 2002-06-20 | 2005-11-28 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
| US7879338B2 (en) * | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
| EP1670824A2 (en) | 2003-09-24 | 2006-06-21 | Montana State University | Norovirus monoclonal antibodies and peptides |
| WO2005037223A2 (en) * | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
| US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
| US7481997B1 (en) * | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| US20050260225A1 (en) * | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
| CU23496A1 (es) * | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| JP4993301B2 (ja) | 2004-10-20 | 2012-08-08 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| EP1846439A2 (en) * | 2005-01-31 | 2007-10-24 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| CN101180312A (zh) | 2005-02-18 | 2008-05-14 | 诺华疫苗和诊断公司 | 来自尿路病原性大肠杆菌的免疫原 |
| WO2006097530A2 (en) | 2005-03-18 | 2006-09-21 | Cytos Biotechnology Ag | Cat allergen fusion proteins and uses thereof |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| JP4825958B2 (ja) * | 2005-08-10 | 2011-11-30 | 財団法人ヒューマンサイエンス振興財団 | 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原 |
| US7527801B2 (en) * | 2005-11-22 | 2009-05-05 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and Sapovirus antigens |
| JP2007145775A (ja) * | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスｇｉの高感度検出方法 |
| EP2641613A1 (en) * | 2006-09-29 | 2013-09-25 | Ligocyte Pharmaceuticals, Inc. | Liquid norovirus vaccine formulations comprising toll-like receptor (TLR) agonist as adjuvant |
| US20100266636A1 (en) * | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| CN101918028B (zh) | 2007-09-18 | 2015-01-07 | 莱戈赛特医药股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
| EP2324113B8 (en) | 2008-08-08 | 2018-04-04 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| KR20120125627A (ko) * | 2010-01-21 | 2012-11-16 | 리고사이트 파머슈티컬즈 인코퍼레이티드 | 칼리시바이러스 바이러스 유사 입자들 상에 표적화된 이종 항원 제공 |
-
2009
- 2009-08-10 EP EP09805653.4A patent/EP2324113B8/en active Active
- 2009-08-10 WO PCT/US2009/053249 patent/WO2010017542A1/en not_active Ceased
- 2009-08-10 EP EP18158843.5A patent/EP3382011A1/en active Pending
- 2009-08-10 SG SG2013057732A patent/SG2013057732A/en unknown
- 2009-08-10 CA CA2733589A patent/CA2733589C/en active Active
- 2009-08-10 KR KR1020117005478A patent/KR101793161B1/ko active Active
- 2009-08-10 PL PL09805653T patent/PL2324113T3/pl unknown
- 2009-08-10 JP JP2011522301A patent/JP5852883B2/ja active Active
- 2009-08-10 CN CN200980139886.5A patent/CN102177233B/zh active Active
- 2009-08-10 DK DK09805653.4T patent/DK2324113T3/en active
- 2009-08-10 KR KR1020177030841A patent/KR102118458B1/ko active Active
- 2009-08-10 NO NO09805653A patent/NO2324113T3/no unknown
- 2009-08-10 CN CN201510127943.5A patent/CN104911154A/zh active Pending
- 2009-08-10 AU AU2009279456A patent/AU2009279456B2/en active Active
- 2009-08-10 ES ES09805653.4T patent/ES2668836T3/es active Active
-
2011
- 2011-02-08 US US13/023,363 patent/US8841120B2/en active Active
-
2014
- 2014-07-25 US US14/341,375 patent/US9518096B2/en active Active
-
2015
- 2015-04-02 JP JP2015075955A patent/JP6448445B2/ja active Active
-
2016
- 2016-03-16 HK HK16103047.9A patent/HK1215051A1/zh unknown
-
2017
- 2017-05-15 JP JP2017096499A patent/JP2017153484A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110195113A1 (en) | 2011-08-11 |
| JP5852883B2 (ja) | 2016-02-03 |
| AU2009279456B2 (en) | 2015-02-05 |
| JP6448445B2 (ja) | 2019-01-09 |
| JP2015171363A (ja) | 2015-10-01 |
| KR20170122848A (ko) | 2017-11-06 |
| PL2324113T3 (pl) | 2018-08-31 |
| HK1215051A1 (zh) | 2016-08-12 |
| AU2009279456A2 (en) | 2011-03-31 |
| CN102177233B (zh) | 2015-04-15 |
| AU2009279456A1 (en) | 2010-02-11 |
| SG2013057732A (en) | 2015-02-27 |
| WO2010017542A1 (en) | 2010-02-11 |
| DK2324113T3 (en) | 2018-04-16 |
| CN104911154A (zh) | 2015-09-16 |
| KR102118458B1 (ko) | 2020-06-03 |
| KR20110053994A (ko) | 2011-05-24 |
| CA2733589C (en) | 2021-07-13 |
| EP2324113B8 (en) | 2018-04-04 |
| EP2324113A1 (en) | 2011-05-25 |
| EP2324113B1 (en) | 2018-02-28 |
| EP2324113A4 (en) | 2012-01-04 |
| ES2668836T3 (es) | 2018-05-22 |
| JP2017153484A (ja) | 2017-09-07 |
| KR101793161B1 (ko) | 2017-11-03 |
| CA2733589A1 (en) | 2010-02-11 |
| CN102177233A (zh) | 2011-09-07 |
| JP2011530295A (ja) | 2011-12-22 |
| US9518096B2 (en) | 2016-12-13 |
| US8841120B2 (en) | 2014-09-23 |
| US20150023995A1 (en) | 2015-01-22 |
| EP3382011A1 (en) | 2018-10-03 |